At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
IL-YANG Flu Vaccine QIV 0.5mL +1 morebiological
Likely dose
IL-YANG Flu Vaccine QIV 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects
In Brief
A Phase 2 clinical trial evaluating IL-YANG Flu Vaccine QIV 0.5mL and IL-YANG Flu Vaccine TIV 0.5mL for Influenza, Human. Completed, enrolled 84 participants.
Detailed Summary
This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in healthy Korean males and females 19 to \< 65 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
Primary CompletionApr 2015
First PostedJun 2015
TodayJul 2026
First PostedJun 25, 2015
Enrollment StartFeb 1, 2015
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.0 years ago
Interventions
IL-YANG Flu Vaccine QIV 0.5mLbiological
IL-YANG Flu Vaccine TIV 0.5mLbiological